| This week's sponsor is Premier Research. | | | Rare Oncology Drug Advances. What's In It For You?
Take a look at how new drug development processes and regulatory pathways are helping speed development of novel therapies, including adaptive design strategies, endpoint selection, and effectively using biomarkers. Download our latest white paper now.
Premier Research. It's what we do. Best. |
Featured Story | | | Wednesday, June 14, 2017 Joining many other biopharmas in the difficult race to treat the often-disabling condition lupus, Celgene has published data showing its drug has “positive trends.” |
|
|
| This week's sponsor is Medpace. | | | |
Top Stories Wednesday, June 14, 2017 Life sciences VC Flagship Pioneering has been attracting some big names to its top management and shows no signs of letting up. Wednesday, June 14, 2017 Orum Therapeutics has raised a small series A to help push on with its work on a monoclonal antibody designed to treat undruggable cytosolic targets. Monday, June 12, 2017 “Patient centricity must be grounded in an engagement approach for the patients … ” Jonathan Zung, PhD, Covance. How do clinical research organizations (CROs) respond and support this increasing focus on patient-centric practices? Wednesday, June 14, 2017 A phase 2b trial of Aldeyra Therapeutics’ allergic conjunctivitis candidate ADX-102 has missed its primary endpoint. But the tiny biotech tried to brush off the setback, pointing to other aspects of the data to support its desire to advance the ophthalmic solution into a late-phase trial. Wednesday, June 14, 2017 Jeffrey Kindler’s Centrexion Therapeutics has posted six-month data from a phase 2b trial of its nonopioid treatment for knee pain. Differences in pain levels experienced by patients who took the experimental synthetic form of trans-capsaicin and placebo narrowed over the second half of the trial but remained big enough for Centrexion to claim a victory. Tuesday, June 13, 2017 JSR Corporation bought a majority stake in CDMO KBI Biopharma in early 2015, and now, it has made another major biotech deal to acquire mammalian cell line developer Selexis, planning to combine it with KBI. Wednesday, June 14, 2017 Centogene has raised $28 million to expand its presence in the U.S. and China. The financing sees the rare disease genetic diagnostic specialist turn its back on the venture capital-free approach it took in its early years to bring on board a consortium of investors to support its global ambitions. Tuesday, June 13, 2017 Back in March, a real-world analysis showed SGLT2 diabetes meds from AstraZeneca, Johnson & Johnson and the Eli Lilly-Boehringer team could dramatically cut heart failure hospitalizations and deaths. Now, new analyses confirm those findings—and may make a case for using the meds earlier in treatment, AZ’s execs suggest. | This week's sponsor is Cmed. | | | |
| | | Cancer biotech Athenex has raised $66 million in its initial public offering by offering 6 million shares at $11, the low end of its range. Renaissance Capital brief Oncology biopharma PsiOxus Therapeutics has boosted its operations into a 21,000-square-foot facility in Oxfordshire, U.K., while also opening a new U.S. facility in Plymouth Meeting near Philadelphia. Release McKinsey veteran Tony Tramontin, Ph.D., has become the new CSO and senior vice president of research and development at amino acid-based drug development biotech Axcella. Statement | |
|
Resources Sponsored by Envigo Performing a sophisticated surgery to create a myocardial infarction model. Join us on June 7th at 11:00 AM EDT. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA 2017 BIO International Convention: The Largest Global Biotech Partnering Event of the Year June 19-22 | San Diego, CA Join 1,000 Diagnostics Professionals at Next Generation Dx Summit August 15-18, 2017 | Washington, DC FierceBiotech Executive Breakfast- Tackling the Drug Price Problem: A Town Hall Debate June 21, 2017 | San Diego, CA | 